Viking Therapeutics Inc VKTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VKTX is a good fit for your portfolio.
News
-
Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock's a buy.
-
Thinking about trading options or stock in NVIDIA, Vale, Viking Therapeutics, GigaCloud Technology, or Crowdstrike Holdings?
-
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
-
Thinking about trading options or stock in Advanced Micro Devices, Amazon.com, Intel, GSK, or Viking Therapeutics?
-
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Here's how investors can ride along as a major global commodity market shifts away from China
-
Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount
-
This biotech ETF sees 'breakout' while U.S. small-cap technology stocks lag
Trading Information
- Previous Close Price
- $83.34
- Day Range
- $80.50–84.70
- 52-Week Range
- $8.28–99.41
- Bid/Ask
- $81.60 / $81.85
- Market Cap
- $8.85 Bil
- Volume/Avg
- 4.3 Mil / 7.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 27
Comparables
Valuation
Metric
|
VKTX
|
CBAY
|
EWTX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 23.56 | 12.65 | 4.03 |
Price/Sales | — | 111.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
VKTX
CBAY
EWTX
Financial Strength
Metric
|
VKTX
|
CBAY
|
EWTX
|
---|---|---|---|
Quick Ratio | 18.92 | 10.70 | 18.98 |
Current Ratio | 19.19 | 10.96 | 19.50 |
Interest Coverage | — | −5.27 | — |
Quick Ratio
VKTX
CBAY
EWTX
Profitability
Metric
|
VKTX
|
CBAY
|
EWTX
|
---|---|---|---|
Return on Assets (Normalized) | −23.50% | −30.06% | −24.36% |
Return on Equity (Normalized) | −25.01% | −51.97% | −25.87% |
Return on Invested Capital (Normalized) | −30.29% | −30.87% | −29.82% |
Return on Assets
VKTX
CBAY
EWTX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vzftptxz | Ywk | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rgkyzzcw | Qxwnv | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zdfvybjf | Vrfqgr | $105.6 Bil | |
MRNA
| Moderna Inc | Fnpjhnr | Vhkct | $40.8 Bil | |
BNTX
| BioNTech SE ADR | Xgbptvfs | Zzjhy | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gbdxllvj | Tsngn | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Blbhydjjs | Pjzkwy | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fkpklmdhks | Pfmxmb | $13.6 Bil | |
INCY
| Incyte Corp | Cxzcrmfw | Xfwpx | $12.8 Bil | |
UTHR
| United Therapeutics Corp | Zypbgtsyj | Ljvdf | $10.8 Bil |